Clinical Trials Browser

olutasidenib × Gastrointestinal × 90 days × Clear all

NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Phase 4 Recruiting

CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma